



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd Prifysgol
Bae Abertawe
Swansea Bay University
Health Board

Cadeirydd/Chair: **Emma Woollett**
Prif Weithredwr/Chief Executive: **Mark Hackett**

gofalu am ein gilydd, cydweithio, gwella bob amser
caring for each other, working together, always improving

Rydym yn croesawu gohebiaeth yn y Gymraeg ac yn y Saesneg. We welcome correspondence in Welsh or English.

Dyddiad/Date: 30th June 2021
Ein Cyf / Our Ref: 21-F-031

01639 648363

FOIA.Requests@wales.nhs.uk

[REDACTED]

Corporate Services
Headquarters
1 Talbot Gateway
Baglan
Port Talbot, SA12 7BR

[REDACTED]

I refer to your Freedom of Information Act Request acknowledged by ourselves on 17th June 2021. Your request sought information relating to melanoma and renal cell carcinoma.

Please note the figures below are for the period March to May 2021.

1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma:

- Avelumab + Axitinib - <5
- Axinitib - < 5
- Cabozantinib - 14
- Everolimus - Nil
- Lenvantinib + Everolimus - 8
- Nivolumab - 17
- Nivolumab + Ipilimumab - 5
- Pazopanib - 14
- Pembrolizumab + Axitinib - Nil
- Sunitinib - 6
- Temsirolimus - Nil
- Tivozanib - 11
- Other - Nil

2. How many patients have been treated in the past 3 months with the following agents for melanoma (any stage):

- Cobimetinib - Nil
- Dabrafenib - <5



Pencadlys BIP Bae Abertawe, Un Porthfa Talbot, Port Talbot, SA12 7BR / Swansea Bay UHB Headquarters, One Talbot Gateway, Port Talbot, SA12 7BR

Bwrdd Iechyd Prifysgol Bae Abertawe yw enw gweithredu Bwrdd Iechyd Lleol Prifysgol Bae Abertawe
Swansea Bay University Health Board is the operational name of Swansea Bay University Local Health Board

- Dabrafenib + Trametinib - 25
- Encorafenib + Binimetinib - <5
- Ipilimumab - <5
- Ipilimumab + Nivolumab -7
- Nivolumab - 7
- Pembrolizumab - 18
- Trametinib -Nil
- Vemurafenib - <5
- Vemurafenib + Cobimetinib - Nil
- Other active systemic anti-cancer therapy - <5
- Palliative care only – not centrally recorded on our pharmacy systems

3. If possible, could you please provide the patients treated in the past 3 months with the following agents for metastatic melanoma ONLY:

- Cobimetinib - Nil
- Dabrafenib - <5
- Dabrafenib + Trametinib - 10
- Encorafenib + Binimetinib - <5
- Ipilimumab - < 5
- Ipilimumab + Nivolumab - 6
- Nivolumab - 6
- Pembrolizumab - 5
- Trametinib - Nil
- Vemurafenib - <5
- Vemurafenib + Cobimetinib - Nil
- Other active systemic anti-cancer therapy - <5
- Palliative care only – Not centrally recorded on our pharmacy systems.

Where fewer than 5 has been indicated we are unable to provide you with the exact number of patients as due to the low numbers, there is a potential risk of identifying individuals if this was disclosed. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

I hope this information is helpful. If you require anything further please contact us at FOIA.Requests@wales.nhs.uk.

Under the terms of the Health Board's Freedom of Information policy, individuals seeking access to recorded information held by the Health Board are entitled to request internal review of the handling of their requests. If you would like to complain about the Health Board's handling of your request please contact me directly at the address below or register your complaint via FOIA.Requests@wales.nhs.uk.

If after Internal Review you remain dissatisfied you are also entitled to refer the matter to the information commissioner at the Information Commissioner's Office (Wales), 2nd Floor, Churchill House, Churchill Way, Cardiff, CF10 2HH. Telephone Number: 029 2067 8400.



Yours sincerely

A handwritten signature in black ink, appearing to read 'Pam Wenger', with a horizontal line underneath the name.

On behalf of

Pam Wenger

Director of Corporate Governance

